---
sidebar_position: 74
---

# 文獻 74：Factors Affecting the Receptiveness of Chinese Internists and Surgeons Toward Artificial Intelligence-Driven Drug Prescription

**English Title**: Factors Affecting the Receptiveness of Chinese Internists and Surgeons Toward Artificial Intelligence-Driven Drug Prescription

**中文標題**: 影響中國內科醫生和外科醫生對 AI 驅動藥物處方接受度的因素
**PMID**: 40812739
**期刊**: 未知期刊
**評分**: 中等
**應用領域**: 6
**DOI**: https://doi.org/10.2196/76009

---

## 📌 第一張：核心觀點卡

### 主要發現
低

### 文獻摘要（Abstract）
BACKGROUND: Recently, we developed and tested an autonomous artificial intelligence (AI) agent for prescribing a drug to prevent severe acute graft-versus-host disease in patients receiving human leukocyte antigen haplotype-mismatched hematopoietic cell transplants in a prospective clinical trial. Our experience in this proof-of-concept study suggests that physicians and patients can be receptive to autonomous AI prescription. However, the generalizability of our conclusion requires testing in additional clinical settings. Before broadening the scope of study of AI-driven drug prescriptions, it is important to quantify the factors that influence a physician's receptiveness to AI prescription. OBJECTIVE: We aim to systematically interrogate physicians' receptiveness to AI prescription in China. METHODS: We have designed a research protocol to survey a diverse range of factors that may affect physicians' receptiveness to AI prescription systems, including the physicians' personal attributes and their perceptions of the importance of various technological, institutional, and governmental attributes. The survey will be conducted in 2 phases. In phase 1, the survey will be limited to the Tianjin metropolitan area, enlisting &gt;250 physicians from approximately 2 tier-1, 3 tier-2, and 3 tier-3 hospitals. In phase 2, we will survey metropolitan areas in ≥10 additional province-level administrative divisions, enlisting &gt;1250 additional physicians from &gt;15 tier-1, &gt;15 tier-2, and &gt;15 tier-3 hospitals. We hypothesize that physicians can be broadly classified into distinct psychological profile types, and furthermore, that these types are plausibly mediated by the locales where the physicians are employed and the physicians' demographics, educational and job experience, clinical subspecialties, and previous knowledge of and experience with AI. Clustering methods, including t-distributed stochastic neighbor embedding and hierarchical clustering, will be performed on respondent data to identify the distinct psychological profile types of the physicians. Multiple-variable regression and mediation analyses will be conducted to identify potential underlying mechanisms mediating physicians' receptiveness to AI prescription. RESULTS: At the time of submission of the manuscript, no subjects have been recruited. The survey study was approved by the institutional ethics committee and funded in May 2025, and we started recruiting respondents in May 2025. We plan to complete phase 1 by September 30, 2025, and phase 2 by November 30, 2025. Anonymized survey results and their analyses are expected to be published in a peer-reviewed journal in fall 2026. CONCLUSIONS: We anticipate that data and analytical insights generated from this study will assist policy makers and AI researchers in prioritizing a data-informed sequence of developing and promoting AI prescription tools in successive regions, disciplines, and clinical use cases and inform policy makers to match resource allocation with "AI readiness." INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/76009.

### 關鍵數據
- **研究類型**: 未分類
- **國家/地區**: 待查
- **發表年份**: 待查
- **ROI 數值**: 無數值

### 核心創新點
本研究的主要創新在於：低

---

## ✍️ 第二張：Paraphrase 卡

### 研究目的與方法
本研究聚焦於6領域，旨在探討 AI 技術在醫療場景中的應用。

### 主要貢獻
研究提出了低，為臨床實踐提供了新的解決方案。

### 技術特點
- 應用場景：6
- 創新程度：評分 中等/10
- 期刊影響：發表於 未知期刊

---

## ❓ 第三張：問答卡

### Q1: 這項研究解決了什麼問題？
A: 本研究針對6領域的挑戰，提出了基於 AI 的解決方案。

### Q2: 採用了什麼技術方法？
A: 低

### Q3: 研究的主要成果是什麼？
A: 研究獲得了 中等 分的專家評分，證明了其在6領域的應用價值。

### Q4: 有哪些實際應用場景？
A: 主要應用於6，可用於改善醫療服務品質和效率。

---

## 🤔 第四張：例外卡

### 潛在限制
1. **研究範圍**: 研究評分為 中等/10，可能存在改進空間
2. **地區差異**: 研究來自待查，其他地區適用性需驗證
3. **ROI 數據**: 無數值，經濟效益評估可能不完整

### 需要進一步探討的問題
1. 該技術在不同規模醫院的適用性如何？
2. 長期使用的效果和穩定性是否經過驗證？
3. 與現有系統整合時可能面臨哪些挑戰？

### 批判性思考
- **技術成熟度**: 需要評估從研究到實際部署的距離
- **成本效益**: 無數值，需要更詳細的經濟分析
- **倫理考量**: AI 在6應用時的倫理和隱私問題
- **可推廣性**: 研究結果在其他醫療場景的適用性

---

## 📚 參考資訊
- **PMID**: [40812739](https://pubmed.ncbi.nlm.nih.gov/40812739/)
- **DOI**: https://doi.org/10.2196/76009
- **期刊**: 未知期刊
